http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-1063605-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69c91bbf0395db010b4806f50d808c4e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D243-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D243-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D243-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D243-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D243-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D243-16 |
| filingDate | 1975-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1979-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cb3729b65365bcb045a0eea5415c2ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d436576e28a456240b8e1bff991c37de http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b74b41802e27e4cb95002ad06584670f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c028ee521b90b04c109b0f3f202ea0d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e6cce3e4af81a1e51af4e530e70409b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_604b6c87ca20151ccbf4a88a27f93fce |
| publicationDate | 1979-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-1063605-A |
| titleOfInvention | Benzodiazepine derivatives and a process for the preparation thereof |
| abstract | ABSTRACT OF THE DISCLOSURE New racemic or optically active 4-substituted--1,3,4,5-tetrshydro-2H-1, 4-benzodiazepine-2-one de-rivatives of the general formula (I) (I) wherein R1 stands for hydrogen, halogen, trifluoromethyl, amino or nitro, R2 stands for hydrogen or alkyl, R3 stands for an acyl group derived from a carbonic acid derivative or from an optionally substituted aliphatic, cycloaliphatic or aromatic carboxylic acid, and R6 stands for phenyl or halophenyl, with the proviso that (i) if the compound is racemic, and R2 stands for lower alkyl and R1 stands for hydrogen or halogen, R3 may not stand for a carbamoyl group having a lower alkyl, lower alkenyl, cyclohexyl, phenyl or benzyl substituent, or (ii) if the compound is racemic, and R2 stands for lower alkyl and R1 stands for halogen or tri-fluoromethyl, R3 may not stand for lower alkanoyl, are prepared as follows: a) a racemic or optically active 1,3,4,5-tetra-hydro-2H-1,4-benzodiazepine-2-one derivative of the general formula (II), (II) wherein R1, R2 and R6 each have the same meanings as defined above, is reacted, optionally in the presence of an acid binding agent, with an acid derivative of the general formula (III), R4 - CO - X , (III) prepared optionally directly in the reaction mixture from the appropriate carboxylic acid, wherein X stands for halogen or alkoxy, and R4 stands for halogen; an optionally substituted aliphatic, cycloalipatic or aromatic hydrocarbyl group or an oxy derivative there-of; amino group; or an amino group having an optionally substituted amino, a hydrocarbyl (as defined above) or an acyl substituent, and, if desired, a thus-ob-tanied compound of the general formula (I), wherein R1, R2 and R6 each have the same meanings as defined above and R3 stands for halocarbonyl, is reacted with ammonia or with an amine; or b) a racemic or optically active 1,3,4,5-tetra-hydro-2H-1,4-benzodiazepine-2-one derivative of the general formula (II), wherein R1, R2 and R6 each have the same meanings as defined above, or a salt thereof is reacted with a compound of the general formula (IV), R5 - Y (IV) wherein R5 stands for hydrogen, alkali metal, or an aliphatic, cycloaliphatic or aromatic hydrocarbyl group and Y stands for a group of the formula NCO-or OCN-, and, if desired, any racemic or optically ac-tive compound of the general formula (I), wherein R1, R3 and R6 each have the same meanings as defined above and R2 stands for hydrogen, is alkylated. The above compounds possess excellent tranquillo--sedative effects and can be used in the therapy pri-marily for the treatment of depressive conditions. |
| priorityDate | 1974-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 174.